Kyverna names Nadia Dac as Chief Commercial Officer ahead of miv-cel launch
Kyverna Therapeutics appointed Nadia Dac as Chief Commercial Officer effective May 4, granting her 300,000 stock options vesting over four years. Dac brings over 30 years of U.S. and global commercial leadership and will spearhead the miv-cel launch for stiff person syndrome and broader neuroimmunology franchise.
1. Leadership Appointment
Kyverna Therapeutics appointed Nadia Dac as Chief Commercial Officer effective May 4, 2026, marking a pivotal shift to a commercial-stage entity. Dac will lead the commercialization of mivocabtagene autoleucel (miv-cel, KYV-101), targeting stiff person syndrome and expanding into additional neuroimmunology indications.
2. Extensive Commercial Experience
With over 30 years in commercial leadership, Dac has overseen product launches and scaled teams across rare diseases and neurology at companies including Omeros, Alder, AbbVie and Novartis. Her track record includes launching Yartemlea® and Vyepti®, as well as supporting multiple sclerosis therapies like Gilenya® and Extavia®.
3. Stock Option Grant Incentive
To support her role, Kyverna granted Dac an inducement option to purchase 300,000 common shares under its 2024 Equity Incentive Plan. The options vest over four years—25% after one year and the remainder monthly—at an exercise price equal to the closing stock price on the grant date.